Early enteral administration of a formula (Impactρ) supplemented with arginine, nucleotides, and fish oil in intensive care unit patients

Results of a multicenter, prospective, randomized, clinical trial

R. H. Bower, F. B. Cerra, B. Bershadsky, J. J. Licari, D. B. Hoyt, G. L. Jensen, C. T. Van Buren, Michael Rothkopf, J. M. Daly, B. R. Adelsberg

Research output: Contribution to journalArticle

501 Citations (Scopus)

Abstract

Objective: To determine if early enteral feeding, in an intensive care unit (ICU) patient population, using a formula supplemented with arginine, dietary nucleotides, and fish oil (Impact®), results in a shorter hospital stay and a reduced frequency of infectious complications, when compared with feeding a common use enteral formula (Osmolite HN®). Design: A prospective, randomized, double-blind, multicenter trial. Setting: ICUs in eight different hospitals. Patients: Of 326 patients enrolled in the study, 296 patients were eligible for analysis. They were admitted to the ICU after an event such as trauma, surgery, or sepsis, and met a risk assessment screen (Acute Physiology and Chronic Health Evaluation II [APACHE II] score of ≥10, or a Therapeutic Intervention Scoring System score of ≥20) and study eligibility requirements. Patients were stratified by age (<60 or ≥60 yrs of age) and disease (septic or systemic inflammatory response syndrome). Interventions: Patients were enrolled and full-strength tube feedings were initiated within 48 hrs of the study entry event. Enteral feedings were advanced to a target volume of 60 mL/hr by 96 hrs of the event. One hundred sixty-eight patients were randomized to receive the experimental formula, and 158 patients were randomized to receive the common use control formula. Measurements and Main Results: Both groups tolerated early enteral feeding well, and the frequency of tube feeding-related complications was low. There were no significant differences in nitrogen balance between groups on study days 4 and 7. Patients receiving the experimental formula had a significant (p = .0001) increase in plasma arginine and ornithine concentrations by study day 7. Plasma fatty acid profiles demonstrated higher concentrations of linoleic acid (p < .01) in the patients receiving the common use formula and higher concentrations of eicosapentaenoic and docosahexaenoic acid (p < .01) in the patients receiving the experimental formula. The mortality rate was not different between the groups and was significantly (p < .001) lower than predicted by the admission severity scores in both feeding groups. In patients who received at least 821 mL/day of the experimental formula, the hospital median length of stay was reduced by 8 days (p < .05). In patients stratified as septic, the median length of hospital stay was reduced by 10 days (p < .05), along with a major reduction in the frequency of acquired infections (p < .01) in the patients who received the experimental formula. In the septic subgroup fed at least 821 mL/day, the median length of stay was reduced by 11.5 days, along with a major reduction in acquired infections (both p < .05) in the patients who received the experimental formula. Conclusions: Early enteral feeding of the experimental formula was safe and well tolerated in ICU patients. In patients who received the experimental formula, particularly if they were septic on admission to the study, a substantial reduction in hospital length of stay was observed, along with a significant reduction in the frequency of acquired infections.

Original languageEnglish (US)
Pages (from-to)436-449
Number of pages14
JournalCritical Care Medicine
Volume23
Issue number3
DOIs
StatePublished - Mar 24 1995

Fingerprint

Fish Oils
Small Intestine
Intensive Care Units
Arginine
Nucleotides
Randomized Controlled Trials
Enteral Nutrition
Length of Stay
Infection
Unsaturated Dietary Fats
Systemic Inflammatory Response Syndrome
APACHE
Ornithine
Eicosapentaenoic Acid
Docosahexaenoic Acids
Linoleic Acid

All Science Journal Classification (ASJC) codes

  • Critical Care and Intensive Care Medicine

Cite this

Bower, R. H. ; Cerra, F. B. ; Bershadsky, B. ; Licari, J. J. ; Hoyt, D. B. ; Jensen, G. L. ; Van Buren, C. T. ; Rothkopf, Michael ; Daly, J. M. ; Adelsberg, B. R. / Early enteral administration of a formula (Impactρ) supplemented with arginine, nucleotides, and fish oil in intensive care unit patients : Results of a multicenter, prospective, randomized, clinical trial. In: Critical Care Medicine. 1995 ; Vol. 23, No. 3. pp. 436-449.
@article{4bea68bb39bf411cbd0b4277bd777783,
title = "Early enteral administration of a formula (Impactρ) supplemented with arginine, nucleotides, and fish oil in intensive care unit patients: Results of a multicenter, prospective, randomized, clinical trial",
abstract = "Objective: To determine if early enteral feeding, in an intensive care unit (ICU) patient population, using a formula supplemented with arginine, dietary nucleotides, and fish oil (Impact{\circledR}), results in a shorter hospital stay and a reduced frequency of infectious complications, when compared with feeding a common use enteral formula (Osmolite HN{\circledR}). Design: A prospective, randomized, double-blind, multicenter trial. Setting: ICUs in eight different hospitals. Patients: Of 326 patients enrolled in the study, 296 patients were eligible for analysis. They were admitted to the ICU after an event such as trauma, surgery, or sepsis, and met a risk assessment screen (Acute Physiology and Chronic Health Evaluation II [APACHE II] score of ≥10, or a Therapeutic Intervention Scoring System score of ≥20) and study eligibility requirements. Patients were stratified by age (<60 or ≥60 yrs of age) and disease (septic or systemic inflammatory response syndrome). Interventions: Patients were enrolled and full-strength tube feedings were initiated within 48 hrs of the study entry event. Enteral feedings were advanced to a target volume of 60 mL/hr by 96 hrs of the event. One hundred sixty-eight patients were randomized to receive the experimental formula, and 158 patients were randomized to receive the common use control formula. Measurements and Main Results: Both groups tolerated early enteral feeding well, and the frequency of tube feeding-related complications was low. There were no significant differences in nitrogen balance between groups on study days 4 and 7. Patients receiving the experimental formula had a significant (p = .0001) increase in plasma arginine and ornithine concentrations by study day 7. Plasma fatty acid profiles demonstrated higher concentrations of linoleic acid (p < .01) in the patients receiving the common use formula and higher concentrations of eicosapentaenoic and docosahexaenoic acid (p < .01) in the patients receiving the experimental formula. The mortality rate was not different between the groups and was significantly (p < .001) lower than predicted by the admission severity scores in both feeding groups. In patients who received at least 821 mL/day of the experimental formula, the hospital median length of stay was reduced by 8 days (p < .05). In patients stratified as septic, the median length of hospital stay was reduced by 10 days (p < .05), along with a major reduction in the frequency of acquired infections (p < .01) in the patients who received the experimental formula. In the septic subgroup fed at least 821 mL/day, the median length of stay was reduced by 11.5 days, along with a major reduction in acquired infections (both p < .05) in the patients who received the experimental formula. Conclusions: Early enteral feeding of the experimental formula was safe and well tolerated in ICU patients. In patients who received the experimental formula, particularly if they were septic on admission to the study, a substantial reduction in hospital length of stay was observed, along with a significant reduction in the frequency of acquired infections.",
author = "Bower, {R. H.} and Cerra, {F. B.} and B. Bershadsky and Licari, {J. J.} and Hoyt, {D. B.} and Jensen, {G. L.} and {Van Buren}, {C. T.} and Michael Rothkopf and Daly, {J. M.} and Adelsberg, {B. R.}",
year = "1995",
month = "3",
day = "24",
doi = "10.1097/00003246-199503000-00006",
language = "English (US)",
volume = "23",
pages = "436--449",
journal = "Critical Care Medicine",
issn = "0090-3493",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

Early enteral administration of a formula (Impactρ) supplemented with arginine, nucleotides, and fish oil in intensive care unit patients : Results of a multicenter, prospective, randomized, clinical trial. / Bower, R. H.; Cerra, F. B.; Bershadsky, B.; Licari, J. J.; Hoyt, D. B.; Jensen, G. L.; Van Buren, C. T.; Rothkopf, Michael; Daly, J. M.; Adelsberg, B. R.

In: Critical Care Medicine, Vol. 23, No. 3, 24.03.1995, p. 436-449.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Early enteral administration of a formula (Impactρ) supplemented with arginine, nucleotides, and fish oil in intensive care unit patients

T2 - Results of a multicenter, prospective, randomized, clinical trial

AU - Bower, R. H.

AU - Cerra, F. B.

AU - Bershadsky, B.

AU - Licari, J. J.

AU - Hoyt, D. B.

AU - Jensen, G. L.

AU - Van Buren, C. T.

AU - Rothkopf, Michael

AU - Daly, J. M.

AU - Adelsberg, B. R.

PY - 1995/3/24

Y1 - 1995/3/24

N2 - Objective: To determine if early enteral feeding, in an intensive care unit (ICU) patient population, using a formula supplemented with arginine, dietary nucleotides, and fish oil (Impact®), results in a shorter hospital stay and a reduced frequency of infectious complications, when compared with feeding a common use enteral formula (Osmolite HN®). Design: A prospective, randomized, double-blind, multicenter trial. Setting: ICUs in eight different hospitals. Patients: Of 326 patients enrolled in the study, 296 patients were eligible for analysis. They were admitted to the ICU after an event such as trauma, surgery, or sepsis, and met a risk assessment screen (Acute Physiology and Chronic Health Evaluation II [APACHE II] score of ≥10, or a Therapeutic Intervention Scoring System score of ≥20) and study eligibility requirements. Patients were stratified by age (<60 or ≥60 yrs of age) and disease (septic or systemic inflammatory response syndrome). Interventions: Patients were enrolled and full-strength tube feedings were initiated within 48 hrs of the study entry event. Enteral feedings were advanced to a target volume of 60 mL/hr by 96 hrs of the event. One hundred sixty-eight patients were randomized to receive the experimental formula, and 158 patients were randomized to receive the common use control formula. Measurements and Main Results: Both groups tolerated early enteral feeding well, and the frequency of tube feeding-related complications was low. There were no significant differences in nitrogen balance between groups on study days 4 and 7. Patients receiving the experimental formula had a significant (p = .0001) increase in plasma arginine and ornithine concentrations by study day 7. Plasma fatty acid profiles demonstrated higher concentrations of linoleic acid (p < .01) in the patients receiving the common use formula and higher concentrations of eicosapentaenoic and docosahexaenoic acid (p < .01) in the patients receiving the experimental formula. The mortality rate was not different between the groups and was significantly (p < .001) lower than predicted by the admission severity scores in both feeding groups. In patients who received at least 821 mL/day of the experimental formula, the hospital median length of stay was reduced by 8 days (p < .05). In patients stratified as septic, the median length of hospital stay was reduced by 10 days (p < .05), along with a major reduction in the frequency of acquired infections (p < .01) in the patients who received the experimental formula. In the septic subgroup fed at least 821 mL/day, the median length of stay was reduced by 11.5 days, along with a major reduction in acquired infections (both p < .05) in the patients who received the experimental formula. Conclusions: Early enteral feeding of the experimental formula was safe and well tolerated in ICU patients. In patients who received the experimental formula, particularly if they were septic on admission to the study, a substantial reduction in hospital length of stay was observed, along with a significant reduction in the frequency of acquired infections.

AB - Objective: To determine if early enteral feeding, in an intensive care unit (ICU) patient population, using a formula supplemented with arginine, dietary nucleotides, and fish oil (Impact®), results in a shorter hospital stay and a reduced frequency of infectious complications, when compared with feeding a common use enteral formula (Osmolite HN®). Design: A prospective, randomized, double-blind, multicenter trial. Setting: ICUs in eight different hospitals. Patients: Of 326 patients enrolled in the study, 296 patients were eligible for analysis. They were admitted to the ICU after an event such as trauma, surgery, or sepsis, and met a risk assessment screen (Acute Physiology and Chronic Health Evaluation II [APACHE II] score of ≥10, or a Therapeutic Intervention Scoring System score of ≥20) and study eligibility requirements. Patients were stratified by age (<60 or ≥60 yrs of age) and disease (septic or systemic inflammatory response syndrome). Interventions: Patients were enrolled and full-strength tube feedings were initiated within 48 hrs of the study entry event. Enteral feedings were advanced to a target volume of 60 mL/hr by 96 hrs of the event. One hundred sixty-eight patients were randomized to receive the experimental formula, and 158 patients were randomized to receive the common use control formula. Measurements and Main Results: Both groups tolerated early enteral feeding well, and the frequency of tube feeding-related complications was low. There were no significant differences in nitrogen balance between groups on study days 4 and 7. Patients receiving the experimental formula had a significant (p = .0001) increase in plasma arginine and ornithine concentrations by study day 7. Plasma fatty acid profiles demonstrated higher concentrations of linoleic acid (p < .01) in the patients receiving the common use formula and higher concentrations of eicosapentaenoic and docosahexaenoic acid (p < .01) in the patients receiving the experimental formula. The mortality rate was not different between the groups and was significantly (p < .001) lower than predicted by the admission severity scores in both feeding groups. In patients who received at least 821 mL/day of the experimental formula, the hospital median length of stay was reduced by 8 days (p < .05). In patients stratified as septic, the median length of hospital stay was reduced by 10 days (p < .05), along with a major reduction in the frequency of acquired infections (p < .01) in the patients who received the experimental formula. In the septic subgroup fed at least 821 mL/day, the median length of stay was reduced by 11.5 days, along with a major reduction in acquired infections (both p < .05) in the patients who received the experimental formula. Conclusions: Early enteral feeding of the experimental formula was safe and well tolerated in ICU patients. In patients who received the experimental formula, particularly if they were septic on admission to the study, a substantial reduction in hospital length of stay was observed, along with a significant reduction in the frequency of acquired infections.

UR - http://www.scopus.com/inward/record.url?scp=0028935349&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028935349&partnerID=8YFLogxK

U2 - 10.1097/00003246-199503000-00006

DO - 10.1097/00003246-199503000-00006

M3 - Article

VL - 23

SP - 436

EP - 449

JO - Critical Care Medicine

JF - Critical Care Medicine

SN - 0090-3493

IS - 3

ER -